Lasa Supergenerics Limited (BOM:540702)

Market Cap	883.79M
Revenue (ttm)	1.26B
Net Income (ttm)	-157.66M
Shares Out	n/a
EPS (ttm)	-3.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	809
Average Volume	31,486
Open	16.75
Previous Close	16.67
Day's Range	16.58 - 16.75
52-Week Range	16.07 - 33.49
Beta	n/a
RSI	36.84
Earnings Date	Jun 4, 2025

About Lasa Supergenerics

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, and halquinol, as well as 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2016
• Employees: 77
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540702

Financial Performance

In 2023, Lasa Supergenerics's revenue was 1.04 billion, a decrease of -19.95% compared to the previous year's 1.30 billion. Losses were -217.31 million, -43.73% less than in 2022.